Dr. Karl Thomae Gmbh

Boehringer Ingelheim Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Dr. Karl Thomae Gesellschaft MIT Beschrankter Haftung

Karl Thomae Gmbh

Celamerck Gmbh & Co. Kg

Dr. Karl Tomae Gmbh

Boehringer Ingelheim Gesellschaft MIT Beschrankter Haftung

Joachim Heider

Volkhard Austel

Willi Diederen

Norbert Hauel

Walter Kobinger

Manfred Reiffen

Christian Lillie

Wolfgang Eberlein

Klaus Reinhold Noll

Eberhard Kutter

Rudolf Kadatz

Andreas Bomhard

Jurgen Dammgen

Berthold Narr

Jacobus C Van Meel

Manfred Psiorz

Mark R Player

James M Rinker

Charles Lawrence Cywin

Bao-Ping Zhao

Michael Peter Winters

Scott E Jakes

Mark A Bobko

Renee L Des Jarlais

Walter Haarmann

Jacques Van Meel

Volkard Austel

Walter Haarman

Helmut Pieper

Josef Nickl

Johannes Keck

Gerd Kruger

Joachim Kahling

Disclosed are compounds of formula (I): wherein R, R, Rand Rare defined herein, which are useful as inhibitors SYK kinase and are thus useful for treating diseases resulting from inappropriate mast cell activation, which include allergic and inflammatory diseases. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

1,6 Naphthridines useful as inhibitors of SYK kinase

1,6 naphthyridines useful as inhibitors of SYK kinase

1,6 Naphthyridines useful as inhibitors of SYK kinase

Disclosed are new cyclic amine derivatives of the formula I ##STR1## wherein the substituents are defined in the specification. These compounds are useful as for treating sinus tachycardia.

Cyclic amine derivatives, pharmaceutical compositions containing these

The present invention relates to new heteroaromatic amine derivatives of general formula ##STR1## wherein the substituents are defined hereinbelow, which have valuable pharmacological properties, particularly a heart rate lowering activity and a positive inotropic activity.

Heteroaromatic amine derivatives

Heteroaromatic amine derivatives, pharmaceutical compositions containing

The present invention relates to new naphthyl derivatives of general formula ##STR1## wherein N represents the number 1 or 2,

Naphthyl derivatives, pharmaceutical compositions containing these

The invention relates to new imidazo-benzoxazinones of formula ##STR1## wherein the substituents are defined herein below, which compounds are useful in the treatment of cardiovascular disorders.

Imidazo-benzoxazinones, the preparation thereof and pharmaceutical

Compounds of the formula ##STR1## wherein A, B, C and D are --N.dbd., HN.dbd., R.sub.3 N.dbd., O.dbd.C.dbd., HC.tbd., HO--C.tbd. or R.sub.3 SO.sub.2 --O--C.tbd.; and

2-phenyl-imidazopyridin-ones and also useful as cardiotonics and

Compounds of the formula ##STR1## wherein A, B, C and D are each independently --N.dbd. or --CH.dbd., provided, however, that at least two of them must be --N.dbd., and when A and C are both --N.dbd., at least one or both of B and D must be --N.dbd.; and

2-phenyl-imidazo-pyrazines, -pyridazines and -triazines

The invention relates to new heteroaromatic amine derivatives of formula ##STR1## wherein A represents a --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--or ##STR2## group and B represents a methylene, carbonyl or thiocarbonyl group or A represents a --CO--CO or ##STR3## group and B represents a methylene group, in which the carbon atom marked x is linked to the phenyl nucleus,

(2H)-3-benzazepin-2-ones, their pharmaceutical compositions and their

The invention relates to novel 2-phenyl-imidazoles of the formula ##STR1## and the tautomers and acid addition salts thereof, particularly the pharmacologically acceptable acid addition salts, which exhibit valuable pharmacological properties, particularly an effect on the contractility of the heart muscle. The compounds of Formula I may be prepared by methods conventionally used for similar compounds.

Novel 2-phenyl-imidazoles and pharmaceutical compositions containing same

The invention relates to new imidazo derivatives of the formula ##STR1## wherein 'A-D and R.sup.1 -R.sup.3 are as defined in the specification'. The new compounds have valuable pharmacological properties, particularly antithrombotic and cardiovascular properties such as a cardiotonic activity and/or an effect on blood pressure, and can be prepared using methods known per se.

Imidazo[1,2a]pyridines and their use as cardiotonic agents

Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen; alkyl of 1 to 7 carbon atoms; cycloalkyl of 3 to 7 carbon atoms; monosubstituted alkyl of 1 to 3 carbon atoms, where the substituent is pyridyl, methypyridyl, phenyl, mono-, di- or trisubstituted phenyl, where the substituents on the phenyl ring, which may be identical to or different from each other, are selected from the group consisting of one amino, one dimethylamino, one to two hydroxyls, one to three methoxys and one to three halogens; .omega.-monosubstituted alkyl of 2 to 4 carbon atoms, where the substituent is hydroxyl or di(alkyl of 1 to 3 carbon atoms)amino; phenyl; monohalo-phenyl; unsubstituted or monosubstituted straight or branched alkanoyl of 1 to 6 carbon atoms, where the substituent is phenyl, methoxyphenyl or cycloalkyl of 3 to 7 carbon atoms; or unsubstituted or monosubstituted phenylsulfonyl, where the substituent is methyl or methoxy; and

Benzotriazolyl-4,5-dihydro-3(2H)-pyridazinones

There are disclosed novel imidazole derivatives of the formula. ##STR1## and derivatives of the formula ##STR2## the tautomers thereof, and non-toxic, pharmacologically acceptable addition salts thereof with inorganic or organic acids. The compounds described herein are useful in treating cardiac insufficiency.

Imidazole derivatives and pharmaceutical compositions containing them

Growing community of inventors

Warthausen, Germany

Joachim Heider